Immunotherapy / PD-1 inhibitorPhase 3 trialInvestigational
Avelumab
How it works
Blocks the PD-1 receptor on immune cells, allowing them to recognize and attack cancer cells.
Cancer types
Efficacy
Avelumab has shown promise in improving overall survival in patients with ovarian cancer, particularly when combined with chemotherapy.
Side effects
Mild
Most people tolerate this treatment well. Side effects are generally manageable and do not require stopping treatment.
Evidence from research
| Study | Cancer type | Stage | Efficacy | |
|---|---|---|---|---|
| Testing Treatments for Advanced Triple Negative Breast Cancer | Breast Cancer | phase-2 | — | Source → |
| Testing Palbociclib and Avelumab in Metastatic Triple Negative Breast Cancer | Breast Cancer | phase-1 | — | Source → |
| New Combination Treatment Shows Promise for Rare Neuroendocrine Tumors | Pancreatic Cancer | phase-2 | The 6-month objective response rate was 18% (95% confidence interval: 8-31%), with a median progression-free survival of 5.5 months (95% CI: 3.6-8). | Source → |
| Study Examines Combination Therapy for Advanced Breast Cancer | Breast Cancer | phase-2 | The median progression-free survival on F + P + A was 8.1 months (HR 0.75 [90% CI, 0.50 to 1.12]; = .23). | Source → |
| Avelumab Fails to Show Benefit in Men with Advanced Prostate Cancer | Prostate Cancer | phase-1 | — | Source → |
| Combining Avelumab and Carboplatin in Advanced Prostate Cancer | Prostate Cancer | preclinical | The objective response rate was 17.6%, including one complete response (5.9%). | Source → |
This information is provided for general education only and is not medical advice. Always consult a qualified healthcare professional before making treatment decisions.